176 related articles for article (PubMed ID: 34540318)
1. COVID-19 vaccine candidates and vaccine development platforms available worldwide.
Duman N; ALzaidi Z; Aynekin B; Taskin D; Demirors B; Yildirim A; Sahin IO; Bilgili F; Turanli ET; Beccari T; Bertelli M; Dundar M
J Pharm Anal; 2021 Dec; 11(6):675-682. PubMed ID: 34540318
[TBL] [Abstract][Full Text] [Related]
2. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
3. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
4. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
[TBL] [Abstract][Full Text] [Related]
5. Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Zhang C; Zhou C; Shi L; Liu G
Hum Vaccin Immunother; 2020 Oct; 16(10):2366-2369. PubMed ID: 32961082
[TBL] [Abstract][Full Text] [Related]
6. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
Frederiksen LSF; Zhang Y; Foged C; Thakur A
Front Immunol; 2020; 11():1817. PubMed ID: 32793245
[TBL] [Abstract][Full Text] [Related]
7. Viral vector and nucleic acid vaccines against COVID-19: A narrative review.
Khoshnood S; Ghanavati R; Shirani M; Ghahramanpour H; Sholeh M; Shariati A; Sadeghifard N; Heidary M
Front Microbiol; 2022; 13():984536. PubMed ID: 36118203
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
9. Human and novel coronavirus infections in children: a review.
Rajapakse N; Dixit D
Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 vaccine candidates in rapid development.
Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
[TBL] [Abstract][Full Text] [Related]
11. An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario.
Gudadappanavar AM; Benni J
J Basic Clin Physiol Pharmacol; 2020 Sep; 31(6):. PubMed ID: 32924964
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 vaccines: concerns beyond protective efficacy and safety.
Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
[TBL] [Abstract][Full Text] [Related]
13. The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world.
Sharpe HR; Gilbride C; Allen E; Belij-Rammerstorfer S; Bissett C; Ewer K; Lambe T
Immunology; 2020 Jul; 160(3):223-232. PubMed ID: 32460358
[TBL] [Abstract][Full Text] [Related]
14. A Comprehensive Review of the Protein Subunit Vaccines Against COVID-19.
Heidary M; Kaviar VH; Shirani M; Ghanavati R; Motahar M; Sholeh M; Ghahramanpour H; Khoshnood S
Front Microbiol; 2022; 13():927306. PubMed ID: 35910658
[TBL] [Abstract][Full Text] [Related]
15. Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19).
Bennet BM; Wolf J; Laureano R; Sellers RS
Toxicol Pathol; 2020 Oct; 48(7):800-809. PubMed ID: 32926660
[TBL] [Abstract][Full Text] [Related]
16. Development of Corona-virus-disease-19 Vaccines.
Hasegawa H
JMA J; 2021 Jul; 4(3):187-190. PubMed ID: 34414311
[TBL] [Abstract][Full Text] [Related]
17. Coronavirus disease 2019 (COVID-19): latest developments in potential treatments.
Hon KL; Leung KKY; Leung AK; Qian SY; Chan VP; Ip P; Wong IC
Drugs Context; 2020; 9():. PubMed ID: 32655654
[TBL] [Abstract][Full Text] [Related]
18. Rescue of SARS-CoV-2 from a Single Bacterial Artificial Chromosome.
Ye C; Chiem K; Park JG; Oladunni F; Platt RN; Anderson T; Almazan F; de la Torre JC; Martinez-Sobrido L
mBio; 2020 Sep; 11(5):. PubMed ID: 32978313
[TBL] [Abstract][Full Text] [Related]
19. Coronavirus disease 2019 vaccine: An overview of the progression and current use.
Gocer S; Turk C; Ozguven SV; Doganay M
North Clin Istanb; 2021; 8(5):529-536. PubMed ID: 34909595
[TBL] [Abstract][Full Text] [Related]
20. Novel Stem Cells and Nucleic Acid-Based Vaccine Trials Against Viral Outbreak: A Systematic Evaluation During COVID-2019 Pandemic.
Maurya CK; Misra R; Sharma P; Singh N; Awasthi H; Agrawal R; Misra S; Dwivedi S
Indian J Clin Biochem; 2020 Oct; 35(4):397-409. PubMed ID: 32837030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
